Dementia-related psychosis and the potential role for pimavanserin

By |2022-02-15T08:04:00-08:00February 15th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

No pharmacological agents are approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis (DRP). Pimavanserin, an atypical antipsychotic that acts as a selective serotonin inverse agonist/antagonist at 5-HT2A receptors (and to a lesser extent, at 5-HT2c receptors), is the only FDA-approved treatment for hallucinations and delusions associated with [...]

Benefit Seen in the Use of Intranasal Insulin in Slowing Dementia

By |2019-07-29T16:49:18-07:00July 29th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

Daily intranasal insulin may be effective in slowing progression of mild cognitive impairment (MCI) or Alzheimer's disease (AD), new research suggests. The findings were presented at the Alzheimer's Association International Conference (AAIC) 2019. Investigators found intranasal insulin administered via a novel delivery device slowed the rate of cognitive decline by [...]

Medical marijuana: Do the benefits outweigh the risks?

By |2018-01-25T14:27:56-08:00January 25th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

By Sheila Gupta, Tiffany Phalen, and Sanjay Gupta There is a need for additional treatment options to improve symptoms, enhance the quality of life (QOL), and reduce suffering among patients who have chronic medical illness. Medical marijuana (MM) has the potential to help patients who have certain medical conditions in states where it [...]

JAMA Issues Advance Directives for Dementia

By |2017-11-06T17:57:54-08:00November 6th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Viewpoint November 6, 2017 Advance Directives for Dementia: Meeting a Unique Challenge By Barak Gaster, Eric B. Larson,  and J. Randall Curtis   In the coming years, an increasing number of people will experience dementia. Worldwide, the number of people living with dementia is projected to increase from 47 million in 2015 to 132 million by [...]

Association of Lithium in Drinking Water With the Incidence of Dementia

By |2021-11-11T17:06:32-08:00August 25th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Original Investigation Association of Lithium in Drinking Water With the Incidence of Dementia Lars Vedel Kessing,  Thomas Alexander Gerds,  Nikoline Nygård Knudsen, Lisbeth Flindt Jørgensen, Søren Munch Kristiansen, Denitza Voutchkova, Vibeke Ernstsen, Jörg Schullehner, Birgitte Hansen, Per Kragh Andersen, Annette Kjær Ersbøll Question  Is a higher lithium level in drinking water associated with a decreased incidence of dementia? Findings  In this Danish nationwide, population-based, [...]

Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial (PREADViSE)

By |2021-11-11T17:13:46-08:00March 25th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Richard J. Kryscio, Erin L. Abner, Allison Caban-Holt, et al. Key Points Question Can vitamin E or selenium prevent dementia in asymptomatic older men? Findings The Prevention of Alzheimer’s Disease by Vitamin E and Selenium trial initially enrolled 7540 elderly men who were exposed to the supplements for an average [...]

OPINION: Recent Study Critical of Psychotropic Prescribing in the Elderly May Belie Real World Treatment

By |2021-11-11T17:14:40-08:00February 14th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

The number of retirement-age Americans taking at least three psychiatric drugs more than doubled between 2004 and 2013, even though almost half of them had no mental health diagnosis on record, according to a new study published in JAMA Internal Medicine and reported in today's New York Times. The new [...]

Albuminuria Linked to Increased Risk for Dementia, Cognitive Impairment

By |2021-11-11T17:15:31-08:00December 21st, 2016|Brief Bulletins from the Field, We Know Psychiatry|

Although past research has shown a link between renal dysfunction and cognitive impairment, a new systematic review shows that the presence of albuminuria specifically is also associated with an increased risk of developing cognitive impairment. The meta-analysis of 22 studies, each with at least 100 participants, was carried out to [...]

Commonly Used P.P.I.s Tied to Brain Disease

By |2016-02-23T20:20:29-08:00February 23rd, 2016|We Know Psychiatry|

Proton Pump Inhibitor's (or P.P.I.s), widely available by prescription or over the counter brands like Prevacid, Nexium, and Prilosec, have been tied to Alzheimer's Disease and other dementias, according to German researchers writing in JAMA Neurology. The researchers looked for five years at 73,679 men and women over 75 who were [...]

Title

Go to Top